Millennium Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-31,700
Closed -$209K 6401
2024
Q3
$209K Sell
31,700
-68,300
-68% -$490K ﹤0.01% 5425
2024
Q2
$750K Buy
100,000
+58,700
+142% +$512K ﹤0.01% 4319
2024
Q1
$412K Buy
+41,300
New +$460K ﹤0.01% 4935
2022
Q1
Sell
-60,000
Closed -$1.03M 7404
2021
Q4
$1.03M Buy
+60,000
New +$1.13M ﹤0.01% 4381

Other funds holding RXRX

Millennium Management's RXRX Position: Q1 2026 in Review

Millennium Management increased its Recursion Pharmaceuticals (RXRX) stake by 75% in Q1 2026, buying an estimated $4.31M and bringing the position to 2,612,277 shares worth $8.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

Millennium Management first reported a position in RXRX in Q4 2021 and has held it in 14 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Millennium Management held 2,612,277 shares of Recursion Pharmaceuticals worth $8.02M as of Q1 2026.
  • Millennium Management bought 1,116,438 Recursion Pharmaceuticals shares in Q1 2026, an estimated $4.31M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2400 holding.
  • Millennium Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.